Fig. 4
Comparison of Erenumab vs placebo in terms of A) ≥ 50%, B) ≥ 75%, C) 100% reduction from baseline in MMD at three months
Fig. 4 | Head & Face Medicine
Comparison of Erenumab vs placebo in terms of A) ≥ 50%, B) ≥ 75%, C) 100% reduction from baseline in MMD at three months